NEW YORK (GenomeWeb News) — Merck has licensed RNAi technology from Protiva Biotherapeutics, and Protiva has agreed to drop ongoing litigation against the drug maker’s subsidiary Sirna Therapeutics, Protiva said this week.
Merck will use Protiva’s stable nucleic acid-lipid particles, or SNALP, technology in its pharmaceutical-development programs, Protiva said.
Terms of the non-exclusive license call for Protiva to receive a one-time payment in advance, and to be entitled to royalty payments if Merck markets any products stemming from the license.
Financial terms of the agreement were not disclosed.
The agreement to cease litigation includes an injunction against Sirna handed down by the Superior Court of California in March, Protiva said.
A comprehensive version of this article appears in the current issue of RNAi News, a GenomeWeb Daily News sister publication.